Predictive pathology: A pathologist's perspective

Cancer Forum

Volumn 27, Issue 2, 2003, Pages 100-101

  Waring, P ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; STEM CELL FACTOR RECEPTOR;

CANCER RESEARCH; DRUG ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTION; PROTEIN EXPRESSION; REVIEW;

EID: 0043246702     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. CD Fletcher, JJ Berman, D Corless, F Gorstein F, et al. "Diagnosis of gastrointestinal stromal tumours: A consensus approach." Human Pathology, 33 (2002): 459-65.
2. S Hirota, K Isozaki, Y Moriyama, K Hashimoto, et al. "Gain-of-function mutations in c-kit in human gastrointestinal stromal tumours." Science, 279 (1998): 577-80.
3. H Joensuu, PJ Roberts, M Sarlomo-Rikala, LC Andersson, et al. "Effect of the tyrosone kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumour." NEJM, 344 (2001): 1052-6.
4. GD Demetri, M Von Mehren, CD Blanke, AD Van den Abbeele, et al. "Efficiacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours." NEJM, 347 (2002): 472-3.
5. M Sabah, M Leader, E Kay. "The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem Mol Morphol, 11 (2003): 56-61.